Want to see KROS full AI Analyst Report?
Keros Therapeutics (KROS) Financial Statements
Keros Therapeutics Financial Overview
Keros Therapeutics's market cap is currently $218.89M. The company's EPS TTM is $-3.70; its P/E ratio is -2.98; Keros Therapeutics is estimated to report earnings on November 11, 2026, and the estimated EPS forecast is $-0.94. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 244.06M | $ 3.55M | $ 151.00K | $ 0.00 | $ 20.10M |
| Gross Profit | $ 242.55M | $ 3.55M | $ 151.00K | $ 0.00 | $ 20.10M |
| Operating Income | $ 70.62M | $ -210.83M | $ -169.94M | $ -114.79M | $ -56.37M |
| EBITDA | $ 93.41M | $ -185.82M | $ -152.18M | $ -104.00M | $ -56.35M |
| Net Income | $ 87.01M | $ -187.35M | $ -152.99M | $ -104.68M | $ -58.74M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 287.42M | $ 559.93M | $ 331.15M | $ 279.05M | $ 230.04M |
| Total Assets | $ 338.02M | $ 615.89M | $ 370.02M | $ 306.78M | $ 255.25M |
| Total Debt | $ 16.88M | $ 18.86M | $ 14.44M | $ 13.27M | $ 1.09M |
| Net Debt | $ -270.53M | $ -541.07M | $ -316.70M | $ -265.78M | $ -228.95M |
| Total Liabilities | $ 34.89M | $ 44.33M | $ 37.81M | $ 29.36M | $ 12.08M |
| Stockholders' Equity | $ 303.13M | $ 571.55M | $ 332.21M | $ 277.42M | $ 243.17M |
| Cash Flow | |||||
| Free Cash Flow | $ 105.95M | $ -162.80M | $ -126.97M | $ -71.30M | $ -63.17M |
| Operating Cash Flow | $ 107.50M | $ -160.87M | $ -124.51M | $ -70.06M | $ -62.15M |
| Investing Cash Flow | $ -1.55M | $ -1.93M | $ -2.46M | $ -1.24M | $ -1.02M |
| Financing Cash Flow | $ -378.47M | $ 391.82M | $ 178.96M | $ 120.31M | $ 28.55M |
Currency in USD